Anlotinib Dihydrochloride
CAS No. 1360460-82-7
Anlotinib Dihydrochloride( Anlotinib (AL3818) dihydrochloride | AL3818 dihydrochloride )
Catalog No. M19393 CAS No. 1360460-82-7
Anlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAnlotinib Dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities.
-
DescriptionAnlotinib also known as AL3818 is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration anlotininib targets multiple RTKs including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
-
In Vitro——
-
In Vivo——
-
SynonymsAnlotinib (AL3818) dihydrochloride | AL3818 dihydrochloride
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR2| VEGFR3|c-Kit
-
Research AreaCancer
-
IndicationNon-small cell lung Cancer
Chemical Information
-
CAS Number1360460-82-7
-
Formula Weight480.36
-
Molecular FormulaC23H24Cl2FN3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:87 mg/mL(181.1 mM)
-
SMILESCc1cc2c([nH]1)ccc(c2F)Oc1c2cc(c(cc2ncc1)OCC1(CC1)N)OC.Cl.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yongkun Sun et al. Safety pharmacokinetics and antitumor properties of anlotinib an oral multi-target tyrosine kinase inhibitor in patients with advanced refractory solid tumors. Journal of Hematology & Oncology20169:105
molnova catalog
related products
-
SCR-1481B1
SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor.
-
Tyrosine kinase-IN-1
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor(KDR Flt-1 FGFR1 and PDGFRα with IC50s of 4nM 20nM 4nM 2 nM respectively).
-
Fargesin
Fargesin as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats.
Cart
sales@molnova.com